
- /
- Supported exchanges
- / F
Krystal Biotech Inc (4KB F) stock market data APIs
Krystal Biotech Inc Financial Data Overview
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Krystal Biotech Inc data using free add-ons & libraries
Get Krystal Biotech Inc Fundamental Data
Krystal Biotech Inc Fundamental data includes:
- Net Revenue: 242 M
- EBITDA: 69 145 K
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-09
- EPS/Forecast: -0.76
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Krystal Biotech Inc News

Strength Seen in Ginkgo Bioworks (DNA): Can Its 14.5% Jump Turn into More Strength?
Ginkgo Bioworks Holdings, Inc. (DNA) shares ended the last trading session 14.5% higher at $16.36. The jump came on an impressive volume with a higher-than-average number of shares changing hands in t...


Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
Krystal Biotech, Inc. PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will re...

Is the Options Market Predicting a Spike in Krystal Biotech (KRYS) Stock?
Investors in Krystal Biotech, Inc. KRYS need to pay close attention to the stock based on moves in the options market lately. That is because the Feb. 21, 2025 $100 Callhad some of the highest implied...

US Growth Companies With High Insider Ownership In January 2025
As the U.S. markets continue to rally, buoyed by President Trump's recent executive actions and a positive economic outlook, investors are increasingly focused on growth companies with solid fundament...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.